Products with Antibacterial bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3865 | Purpureaside C |
| 1. Purpureaside C has significant proinflammatory, antimicrobial and immunomodulating effects. | |
| BCN3868 | Desmethylbellidifolin |
| 1. Desmethylbellidifolin shows stronger antioxidative properties than those of butylated hydroxytoluene (BHT) and α-tocopherol. 2. Desmethylbellidifolin exhibits at the dose of 200 ug/disk a significant inhibition of the growth of Staphylococcus aureus. 3. Dimethylbellidifolin shows mutagenicity in Salmonella typhimurium TA100, TA98, TA97, and TA2637 by the preincubation method. | |
| BCN3869 | Alliin |
| 1. Alliin protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response, alliin may be used as an anti-inflammatory agent in the treatment of ALI. 2. Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase. 3. Alliin has a good antiglycating effect and hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. 4. Alliin and sabinene have detectable levels of antimicrobial activity. 5. Alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. | |
| BCN3884 | Brevifolincarboxylic acid |
| 1. Brevifolincarboxylic acid shows marked inhibitory effects on aryl hydrocarbon receptor -based bioassay activation by TCDD, and its effect is dose dependent. 2. Brevifolincarboxylic acid (IC50 = 18.0 uM) shows good antioxidant activity. 3. Brevifolincarboxylic acid shows moderate antibacterial activity against Salmonella enteritidis , Salmonella typhimurium , and Salmonella abony. | |
| BCN3892 | Cowaxanthone B |
| 1. Cowaxanthone B shows weak antibacterial activity. | |
